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 The syndrome of pyrexia of unknown origin (PUO) was 
ﬁrst deﬁned in 1961 but remains a clinical challenge for 
many physicians. Different subgroups with PUO have been 
suggested, each requiring different investigative strategies: 
classical, nosocomial, neutropenic and HIV-related. This could 
be expanded to include the elderly as a ﬁfth group. The causes 
are broadly divided into four groups: infective, inﬂammatory, 
neoplastic and miscellaneous. Increasing early use of positron 
emission tomography–computed tomography (PET-CT) and 
the development of new molecular and serological tests for 
infection have improved diagnostic capability, but up to 
50% of patients still have no cause found despite adequate 
investigations. Reassuringly, the cohort of undiagnosed 
patients has a good prognosis. In this article we review the 
possible aetiologies of PUO and present a systematic clinical 
approach to investigation and management of patients, 
recommending potential second-line investigations when the 
aetiology is unclear. 
 Introduction 
 The deﬁnition of pyrexia of unknown origin (PUO) dates back 
to 1961; it was described as a persistent fever above 38.3°C 
(100°F) that evades diagnosis for at least 3 weeks, including 
1 week of investigation in hospital. 1 This deﬁnition has evolved 
with faster and more accurate diagnostic techniques and 
changing models of care, and a week of hospitalisation is no 
longer considered essential. Different subgroups with PUO have 
been suggested, each requiring different investigative strategies: 
classical, nosocomial, neutropenic and HIV-related. 2 Pyrexia of 
unknown origin in the elderly tends to be considered under the 
classical heading, but the presentation, underlying conditions 
and subsequent management differ considerably from PUO in a 
younger adult age group. Pyrexia of unknown origin in the over 65s 
could be considered a ﬁfth category. 3,4 
 The causes of PUO can be considered in four categories: 
infective, inﬂammatory, neoplastic and miscellaneous. The relative 
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 Key points 
 When investigating a patient with pyrexia of unknown origin 
(PUO), consider possible aetiologies in each of the following 
four broad categories: infective, inﬂammatory, neoplastic and 
miscellaneous. Address each in turn. Pyrexia of unknown origin 
is a diagnostic challenge and early involvement of specialists is 
important 
 The balance of causes of PUO varies over time and across 
different patient populations 
 Investigations should be undertaken based on the most likely 
cause(s). Blanket investigations are not recommended as 
positive or equivocal tests are difﬁcult to interpret in the absence 
of a suggestive exposure history and/or clinical syndrome. This 
can be misleading and potentially cause patient harm 
 Empirical therapeutic trials are not recommended before a 
diagnosis is made, unless the patient is believed to have miliary 
tuberculosis (TB), central nervous system TB, temporal arteritis or 
infective endocarditis with severe sepsis 
 The overall outcome of patients with a PUO is good, especially 
when no cause is found 
 KEYWORDS :  fever ,  pyrexia of unknown origin ,  fever of unknown 
origin ,  pyrexia ,  diagnosis ■ 
prominence of each category has changed over time, with an 
increasing proportion of patients who remain undiagnosed, 
which may be up to 51% of cases. 5 Infectious causes account 
for 17–35% of cases, inﬂammatory causes 24–36%, neoplastic 
causes 10–20% and miscellaneous causes 3–15%. 6 An older 
multimorbid population, increased global travel, HIV infection, 
the increase in organ transplantation and immunomodulation for 
many diseases, evolving diagnostics and changing antimicrobial 
resistance patterns have all changed the management of patients 
with PUO (Fig  1 ). 
 Clinical approach 
 The diagnostic approach to a patient with PUO should be 
methodical. A thorough history is essential and will have to go 
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back months or years to yield clues to potential aetiologies for 
investigation. The pattern of fever (episodic, consistent etc) 
and general health of the patient during and between episodes 
of fever should be ascertained, together with any associated 
past or current symptoms. Enquiry should include a detailed 
past medical and surgical history, all medications the patient 
takes or has taken including over-the-counter drugs, alternative, 
herbal or ‘traditional’ medications, recreational drug use and 
vaccinations. A comprehensive travel history is needed together 
with occupational, environmental, animal and sexual exposures. 
Illness in contacts and a family history of similar illnesses may 
be relevant. This history should be revisited at regular intervals, 
both to highlight clues that were previously missed or initially 
not considered to be relevant and to review any changes in 
symptoms. 
 Patients with a prolonged PUO are often clinically well 
enough to lead a relatively normal life. However, at every 
clinical encounter it must be reviewed whether the patient has 
developed any ‘red ﬂag’ symptoms; these include weight loss, 
increased lethargy, drenching night sweats, inability to perform 
activities of daily living, or changes in other symptomatology and 
physical examination. 
 A comprehensive examination of the patient follows. The ﬁrst 
clinical encounter should include an ‘A, B, C’ approach to ensure 
the patient is clinically stable. Physical features of a systemic 
inﬂammatory response must be elucidated on examination and in 
the ﬁrst instance sepsis should be ruled out. 
 As well as a detailed examination of the respiratory, 
cardiovascular and alimentary systems one must pay special 
attention to other important sources of fever. This includes: full 
examination of the spine and joints; top-to-toe examination 
of the skin for rashes, ulcers, scars, bites, pressure areas and 
abnormalities of the hair and nails; review of dentition; temporal 
arteries; fundoscopy; breast examination, particularly in women; 
and pelvic or rectal examination including the prostate in men. 
Any implant is a potential site of infection and must be examined 
if possible, including prosthetic joints, pacemakers, pacemaker 
wires, central or peripheral vascular lines, shunts, grafts and 
meshes. 
 Investigations should be conducted to conﬁrm or rule out 
the most likely diagnosis/diagnoses, based on the history and 
examination ﬁndings. Investigation should proceed through at 
least two stages of baseline tests followed by more speciﬁc tests, 
after which each abnormal result should be weighed carefully – 
the more tests that are done, the more false leads will emerge. 
Early blanket testing for all possible aetiologies is inappropriate. 
A baseline set of investigations includes full blood count with a 
differential cell count, renal electrolytes and liver function tests, 
C-reactive protein (CRP) and erythrocyte sedimentation rate 
(ESR), clotting screen, creatine kinase, at least two blood cultures 
(while not receiving antibiotics) and an HIV test. A chest X-ray, 
ultrasound of the abdomen and a urine dipstick should also be 
performed. 
 Potential second-line investigations include microbiological tests, 
imaging and biopsies as described in Table  1 . Each test should only 
be performed when there is a reasonable pretest probability of the 
condition being present and this often requires early involvement 
of other appropriate clinical specialties in the care of patients with 
PUO. The utility and availability of positron emission tomography–
computed tomography (PET-CT) has increased and it is often 
used early in the list of second-line investigations to identify 
metabolically active foci of infection, inﬂammation or cancer as 
possible causes of PUO. 12 
 Infective causes 
 The most common causes of PUO in immunocompetent 
individuals are infective endocarditis (especially culture negative 
endocarditis), discitis, osteomyelitis, occult abscesses and 
infected implanted devices. Patients who have been hospitalised 
in the last 6 months are at increased risk of haematogenous 
spread of infections through invasive procedures and 
intravascular devices. In all cases, a positive microbiological 
diagnosis should be attempted prior to commencing 
antimicrobial therapy, often involving a biopsy of the potentially 
infected tissue or removal of the culprit device. In patients with 
suspected endocarditis and negative blood cultures, fastidious 
and slow-growing bacteria are common aetiological agents. In 
these cases, extended cultures for HACEK organisms (a group 
of fastidious  Haemophilus -like organisms) and serology for 
 Coxiella burnetii (Q fever),  Bartonella spp and  Brucella spp are 
recommended. 13 
 Resistant organisms are becoming increasingly common and 
must be considered in patients with recent (last 6 months) or 
repeated hospitalisations, who have received repeated courses 
of antimicrobials, and those who have been travelling abroad, 
especially if they have had diarrhoea or been hospitalised 
overseas. 
 Elderly patients account for an increasing proportion of patients 
with PUO. It is important to not discount diagnoses such as 
tuberculosis, HIV or syphilis on the basis of age alone. 
 Returning travellers 
 Up to one-quarter of returning travellers cite fever as the chief 
reason for seeking care on return and are more likely to be 
hospitalised than those without fever. 14,15 The National Travel 
Health Network and Centre (NaTHNaC) ( https://travelhealthpro.
0
20
40
60
80
100
120
Ca
us
es
 o
f P
U
O
Ch
ild
re
n
>6
5 
ye
ar
s o
ld
Tr
op
ic
s
Paent populaons
HI
V 
po
si
ve
pa
e
nt
s o
n 
AR
Ta
To
ta
l
Unknown
Miscellaneous
Inﬂammatory
Neoplasc
Infecous
 Fig 1.  The relative causes of pyrexia of unknown origin (PUO) in differ-
ent patient populations expressed as percentages (data from 
references 5 , 7– 11 ).  a Many HIV positive patients have more than one causal 
diagnosis for PUO and therefore the sum of percentages in this category is 
>100%. ART = antiretroviral therapy 
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org.uk ) provides travel information about current outbreaks and 
potential exposures based on the area of travel. 
 A travel history should elicit where the patient has returned 
from (including transits), the length of time spent in each place, 
the type of accommodation used, use of bed nets, the activities 
the patient undertook, what type of food and beverages they 
consumed, and whether they suffered any arthropod or animal 
bites. Details are needed of business and leisure activities including 
animal and freshwater contact, sexual history and possible illness 
in contacts. Vaccinations prior to travel, compliance with malaria 
and other chemoprophylaxis and the use of antimicrobials 
abroad are also important. Most patients with falciparum malaria 
present within 2 months of return, but other species of malaria 
may have incubation periods of a year or more, so travel history 
should extend back for at least 2 years. 16 Patients visiting friends 
and relatives abroad are at increased risk of infections such as 
typhoid and malaria and are also more likely to suffer other serious 
preventable travel-related illnesses compared to other travellers. 
Infections that may present months to years after exposure, such 
as tuberculosis (TB), need to be considered and are more likely in 
areas with large migrant populations. Systematic approaches to 
investigating fever in the returning traveller are published in more 
detail elsewhere. 17 
 It is important to consider less exotic causes for a fever in 
returning travellers such as urinary tract infections, inﬂuenza, 
pneumonia, meningitis and non-infectious conditions, especially 
deep venous thrombosis and pulmonary embolism. 
 Immunosuppressed patients 
 Immunosuppression can be caused by numerous conditions and 
related medications including HIV infection, haematological 
malignancies, organ transplantation, corticosteroids, 
immunomodulators and chemotherapy agents. 
 Pyrexia of unknown origin in patients with HIV infection can 
be caused by HIV seroconversion, opportunistic infections at low 
CD4 cell count levels (especially <200x10 6 cells/L), malignancies 
at all CD4 count levels, and immune reconstitution inﬂammatory 
syndrome (IRIS) after commencing antiretroviral therapy. Patients 
living with HIV often have a high epidemiological risk for infections 
such as TB, invasive non-typhoidal salmonellosis and malaria, 
which can occur at any CD4 count but may present atypically in 
these patients. 
 The risk of immunosuppression in transplant recipients 
is determined by the underlying medical condition which 
necessitated transplant, the duration and type of drug-induced 
immunosuppression pre- and post-transplant, and their 
comorbidities. Acute and chronic transplant rejection can also 
cause fever, the management of which may necessitate further 
immunosuppression. 
 Infections in immunosuppressed patients present atypically, with 
altered incubation periods, attenuated or more severe clinical signs 
and symptoms, and differing yields from diagnostic tests. It is not 
uncommon for immunosuppressed patients to have more than 
one life-threatening infection. 
 Table 1.  Potential second-line investigations for pyrexia of unknown origin 
Infection Inflammatory Neoplastic Miscellaneous 
Echocardiogram, preferably TOE
Line cultures if the patient has an 
intravascular device
Lumbar puncture
Lymph node biopsy
Malaria screen (RDT and three malaria 
films on consecutive days)
PET-CT
Serology for viral hepatitis 
Specialised serological or molecular tests
Spinal MRI
Sputum test for culture (consider an 
induced sputum test if the patient is not 
expectorating)
Stool samples for culture, PCR and OCP
Syphilis serology 
Two to three peripheral blood cultures
Urine culture, plus three early morning 
urines for TB culture in sterile pyuria
Wound swabs
ANA
ANCA
Anti-CCP
Antiphospholipid antibodies (lupus 
anticoagulant and anticardiolipin)
Complement levels
Cryoglobulins
CT chest, abdomen and pelvis
Ferritin
Joint aspiration to detect crystals
LDH
MR or CT angiography
PET-CT
Rheumatoid factor
Serum ACE level
Serum electrophoresis
Serum urate
Temporal artery biopsy
Urine for Bence Jones protein
Colonoscopy
CT chest, abdomen and 
pelvis
Echocardiogram, preferably 
TOE
LDH
PET-CT
Serum calcium
Serum electrophoresis
Tissue, lymph node and/
or bone marrow biopsy for 
histology
Urine for Bence Jones 
protein
Pituitary screen
Synacthen test
Thyroid function tests
 Note: This is not a comprehensive list of investigations to be carried out in every patient with PUO but instead a list of tests that should only be performed when 
there is a reasonable pretest probability of the condition investigated being present. 
 ACE = angiotensin converting enzyme; ANA = anti-nuclear antibodies; ANCA = antineutrophil cytoplasmic antibody; Anti-CCP: anti-cyclic citrullinated peptide; 
CT = computed tomography; LDH = lactate dehydrogenase; MR(I) = magnetic resonance (imaging); OCP = ova, cysts and parasites; PET-CT = positron emission 
tomography–computed tomography; PCR = polymerase chain reaction; RDT = rapid diagnostic test; TB = tuberculosis; TOE = transoesophageal echocardiogram 
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 Immunosuppressed patients have an increased incidence of the 
infections which may present as PUO, especially: 
 > bacterial: pulmonary and extrapulmonary TB, other 
mycobacterial infections, non-typhoidal salmonellosis, 
melioidosis, and syphilis 
 > viral: arboviruses, Coxsackie virus, cytomegalovirus (CMV), 
Epstein–Barr virus (EBV), and parvovirus 
 > fungal: aspergillosis, candidiasis, cryptococcosis, endemic 
mycoses, and histoplasmosis 
 > parasitic: visceral leishmaniasis. 
 Non-infective causes 
 The non-infectious causes of PUO can be broadly categorised 
as inﬂammatory disorders, solid tumours, haematological 
malignancies and miscellaneous (Table  2 ). As the relative 
incidence of infective causes of PUO decreases, non-infective 
causes are becoming more prevalent and can account for up to 
one-third of PUO cases. 5,7 
 Numerous inﬂammatory disorders can cause fever, such 
as systemic rheumatic diseases (eg polymyositis), vasculitic 
processes (eg temporal arteritis), autoinﬂammatory disorders 
(eg Still’s disease) or granulomatous processes (eg sarcoidosis). 
These are often multisystem conditions requiring multiple 
conﬁrmatory investigations and a multidisciplinary approach to 
management. 
 Fever associated with malignancy may be due to the malignant 
process itself or an associated paraneoplastic process, as well 
as opportunistic infections. Criteria for diagnosis of malignancy 
related PUO, including a selective response to naproxen, have been 
summarised elsewhere. 18 
 Drug fever is an under-recognised cause of PUO, particularly 
in the elderly. It usually commences 7–10 days after starting a 
medication but can occur at any time, including months later. If 
fever persists for more than 96 hours after its discontinuation, 
the suspected drug is unlikely to be the cause. 4 Many classes 
of medications can cause fever through different mechanisms 
including antibiotics, anticholinergics, non-steroidals, allopurinol, 
anticonvulsants, anti-hypertensives, antiarrhythmics, and 
antidepressants. 
 There are many rare conditions in the miscellaneous causes of 
PUO, some of the most common of which are listed in Table  2 . It 
is essential to consider factitious (self-induced) fever, especially 
in patients with good medical knowledge and apparently good 
health despite wide-swinging fever patterns. 19 
 Management 
 The management of PUO should be supportive until the cause has 
been determined. Therapeutic trials of antimicrobials or steroids 
are not recommended because they can mask symptoms and 
signs of the underlying disease process. The overall mortality of 
PUO is low, particularly in those well enough to be investigated as 
outpatients. 20 Box  1 lists good practice points in the management 
of patients with PUO. 
 There are three occasions when empirical treatment is 
appropriate: antituberculous therapy for suspected miliary or 
CNS TB, antimicrobials for patients with suspected infective 
endocarditis and signs of sepsis, and steroid treatment for possible 
temporal arteritis. Empirical treatment for TB should always be 
discussed with a specialist, as the risk of drug resistance needs to 
be evaluated for each patient, together with the need for early 
adjunctive steroid therapy for CNS and pericardial TB (at differing 
dosing regimens). 
 One of the most important aspects of management is to 
address the patient’s expectations of diagnosis and treatment. 
It is important to warn them about the need for a methodical 
stepwise approach to investigation, which can be frustrating for 
both the patient and physician and which may not lead to a ﬁrm 
diagnosis. Undiagnosed patients may be reassured that their 
prognosis is likely to be good, despite possible continuation of 
symptoms. ■ 
 Table 2.  Non-infective causes of pyrexia of unknown 
origin 
Category Aetiology 
Inflammatory disorders Behçet’s disease
Familial Mediterranean fever
Felty’s syndrome
Giant cell arteritis and temporal 
arteritis
Gout and pseudogout
Granulomatosis with polyangiitis 
(Wegener’s disease)
Polyarteritis nodosa
Polymyositis
Rheumatoid arthritis
Sarcoidosis
Still’s disease
Systemic lupus erythematosus
Takayasu’s arteritis
Solid tumours Atrial myxoma
Colonic cancer
Hepatic carcinoma
Metastatic disease
Pancreatic cancer
Renal cell carcinoma
Haematological malignancy Leukaemia
Lymphoma
Multiple myeloma
Myeloproliferative disorders
Miscellaneous Drug fever
Factitious fever
Hypoadrenalism
Hypothalamic dysfunction
Inflammatory bowel disease
Thyroiditis
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 Box 1.  Good practice points in the management of 
pyrexia of unknown origin 
There are many pitfalls in the investigation and 
management of pyrexia of unknown origin (PUO). The 
following good-practice points are recommended. 
>  Ensure a thorough history, examination and baseline 
investigation panel have been done.
>  Return to the patient’s history and examination at regular 
intervals.
>  Consider non-infectious causes of a fever early on in the 
patient’s journey.
>  All patients with PUO should have an HIV test.
>  Exclude malaria in patients with a history of relevant travel 
within the last 2 years.
>  A positive tuberculin or interferon gamma release assay is 
not diagnostic for TB: microbiological confirmation through 
bacterial culture or molecular testing is required.
>  Do not give empirical antimicrobial or steroid trials.
>  Be cautious with the interpretation of some serological tests 
as some perform poorly with high false positive and false 
negative rates.
>  Do not perform serological testing if there is no history of 
exposure to the pathogen you are testing for.
>  Perform PET-CT testing early in the patient’s diagnostic 
journey when there are no localising clues in the history or 
examination.
>  Ensure that the patient is aware of the strong possibility of no 
diagnosis being made.
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